Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
about
NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinomaSimvastatin Inhibits Cell Proliferation and Migration in Human Anaplastic Thyroid Cancer.Refractory thyroid carcinoma: which systemic treatment to use?Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates
P2860
Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Targeted next-generation seque ...... in anaplastic thyroid cancer.
@en
Targeted next-generation seque ...... in anaplastic thyroid cancer.
@nl
type
label
Targeted next-generation seque ...... in anaplastic thyroid cancer.
@en
Targeted next-generation seque ...... in anaplastic thyroid cancer.
@nl
prefLabel
Targeted next-generation seque ...... in anaplastic thyroid cancer.
@en
Targeted next-generation seque ...... in anaplastic thyroid cancer.
@nl
P2093
P2860
P50
P1433
P1476
Targeted next-generation seque ...... s in anaplastic thyroid cancer
@en
P2093
Dagmar Führer
Katharina König
Kurt Werner Schmid
Soeren Latteyer
Vera Tiedje
P2860
P2888
P304
P356
10.1007/S12020-016-1080-9
P577
2016-10-01T00:00:00Z